Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
NCT04555161 · View on ClinicalTrials.gov ↗
Study Summary
This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
Conditions Studied
Interventions
- DEVICE Aria CV Pulmonary Hypertension System
Study Locations (12)
California
- University of California - San Diego — La Jolla
- University of California-Los Angeles — Los Angeles
Minnesota
- University of Minnesota — Minneapolis
- Mayo Clinic — Rochester
New York
- Cornell University — New York
- University of Rochester — New York
Ohio
- The Christ Hospital — Cincinnati
- Ohio Health — Columbus
Indiana
- St. Vincent Health — Indianapolis
Massachusetts
- Brigham and Women's Hospital — Boston
South Carolina
- Medical University of South Carolina — Charleston
Wisconsin
- Aurora St Luke's Medical Center — Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2026-10 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04555161
The ClinicalTrials.gov registry entry for NCT04555161 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aria CV, which has 29 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention — of which Aria CV Pulmonary Hypertension System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04555161 reports 12 study locations spanning 8 distinct geographic areas — top geographies include California, Minnesota, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04555161 about?
NCT04555161 is a clinical study titled "Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System". This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
What is the current status of trial NCT04555161?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-03-15. Estimated completion is 2026-10.
What conditions does trial NCT04555161 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Right Heart Dysfunction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04555161?
The interventions under investigation include: Aria CV Pulmonary Hypertension System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04555161?
This trial is sponsored by Aria CV, which has 29 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04555161 being conducted?
This trial has 12 study locations across California, Indiana, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.